⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540412 | 0.84 | — | — | |
| SCHEMBL1243356 | 0.82 | TSHR (0.42) | — | |
| SCHEMBL11745768 | 0.80 | TSHR (0.46) | — | |
| SCHEMBL31588184 | 0.80 | TSHR (0.46) | — | |
| SCHEMBL23696464 | 0.80 | TSHR (0.46) | — | |
| SCHEMBL24672926 | 0.80 | TSHR (0.46) | — | |
| SCHEMBL22298010 | 0.79 | — | — | |
| SCHEMBL22360293 | 0.77 | — | — | |
| SCHEMBL20751526 | 0.77 | LSS (0.42) | — | |
| SCHEMBL24733629 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116813619-A | Macrocyclic inhibitors of Wee1 | 南京正大天晴制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20160355527-A1 | COMPOUNDS AS TYROSINE KINASE MODULATORS | ALLERGAN INC (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2014100764-A2 | METHODS OF INHIBITING PRMT5 | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7816539-B2 | Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2010-10-19 | — | — | US | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7501525-B2 | Derivatives of benzimidazole and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-03-10 | — | — | US | disclosed |
| US-20080139619-A1 | Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) | 2008-06-12 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| EP-1235786-A2 | METHOD FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM N.V. (NL) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001042173-A2 | METHOD FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS | DSM N.V. (NL) | 2001-06-14 | — | — | WO | disclosed |